← Leaderboards
Philip Hahnfeldt
Dana-Farber Cancer Institute
$1,123,526
Attributed
$1,123,526
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,123,526 · 1
By mechanism
R01$1,123,526 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Thomas S. Kupper$36,607,647
- A Thomas Look$30,189,128
- David Morse Livingston$29,482,838
- D Gary Gilliland$5,135,266
- Joan Siefert Brugge$26,786,782
Others in their field
Top investigators on “Neoplasm /Cancer Remission /Regression”
- Hans Schreiber · University Of Chicago$4,824,716
- Arie S Belldegrun · University Of California Los Angeles$4,187,383
- Scott A. Waldman · Thomas Jefferson University$4,081,089
- Anna-Barbara None Moscicki · University Of California San Francisco$3,673,478
- Gloria Yf Ho · Yeshiva University$2,374,801
- Dean W Felsher · Stanford University$2,228,447
Research focus
Neoplasm /Cancer Remission /RegressionMathematical ModelComputer SimulationDrug InteractionsGuanosinetriphosphatase Activating ProteinAngiogenesis InhibitorsCell MigrationNeoplasm /CancerNeoplasm /Cancer PharmacologyNeoplastic CellTissue /Cell CultureAngiostatinsNeoplasm /Cancer ChemotherapyHistologyLaboratory MouseDogsModel Design /Development
Grant awards (6)
Qualifying effectiveness of angiogenic inhibitors$152,350
R01 · FY2004 · CA
Qualifying effectiveness of angiogenic inhibitors$89,427
R01 · FY2004 · CA
Qualifying effectiveness of angiogenic inhibitors$230,850
R01 · FY2003 · CA
Qualifying effectiveness of angiogenic inhibitors$230,963
R01 · FY2002 · CA
Qualifying effectiveness of angiogenic inhibitors$231,638
R01 · FY2001 · CA
QUANTIFYING EFFECTIVENESS OF ANGIOGENIC INHIBITORS$188,298
R01 · FY2000 · CA